Aspirin is a safe and effective thromboembolic prophylaxis after total knee arthroplasty: a systematic review and meta‐analysis

Abstract

AbstractPurposePatients undergoing total knee arthroplasty (TKA) are at high risk for thromboembolic events compared to non‐surgical patients. Both anticoagulants and antiplatelet agents are used as antithrombotic prophylaxis in TKA. The aim of this review is to understand the role of aspirin in the prevention of thromboembolic events and to compare its efficacy and safety with the main anticoagulants used in antithromboembolic prophylaxis in TKA.MethodsA systematic review and meta‐analysis was performed according to the PRISMA guidelines. An electronic systematic search was conducted using PubMed, Scopus, and the Cochrane Central Registry to evaluate studies that compared aspirin with other anticoagulants, in terms of deep venous thrombosis and pulmonary embolism after TKA. The meta‐analysis compared the rate of complications between aspirin and other anticoagulants.ResultsThirteen studies were included in the systematic review for a total of 163,983 patients, and 10 studies were included in the meta‐analysis. The meta‐analysis demonstrated no statistically significant differences between aspirin and other anticoagulants in terms of the rate of deep venous thrombosis (OR 0.93, 95% CI 0.81–1.08, p = 0.35) and pulmonary embolism (OR 0.89, 95% CI 0.56–1.41, p = 0.61).ConclusionAspirin is safe, effective, and not inferior to other main anticoagulants in preventing thromboembolic events following TKA.